Fyrand O
Hudavdelingen Rikshospitalet, Oslo.
Tidsskr Nor Laegeforen. 1990 May 10;110(12):1513-4.
Since 1982, systemic Roaccutan has been used to treat acne that is resistant to traditional therapy. The treatment produces certain side effects and a potential for teratogenesis. The result has been worldwide reports of a number of malformed and abnormal infants. In the present questionnaire presented to 94 Norwegian women of child-bearing potential, no pregnancy occurred during the treatment period. Before start of treatment, all patients agreed to have an abortion if conception occurred during treatment. The article discusses the type of contraception, the quality of information and the effect of treatment upon the acne condition. The study confirms the importance of Roaccutan in the treatment of cystic acne, and shows that the Norwegian prescription routine for Roaccutan is adequate.
自1982年以来,系统性使用Roaccutan(异维甲酸)治疗对传统疗法耐药的痤疮。该治疗会产生某些副作用以及致畸可能性。结果是全球范围内有许多关于畸形和异常婴儿的报道。在向94名有生育潜力的挪威女性发放的本次调查问卷中,治疗期间未发生妊娠。在开始治疗前,所有患者均同意如果在治疗期间怀孕则进行人工流产。本文讨论了避孕类型、信息质量以及治疗对痤疮病情的影响。该研究证实了Roaccutan在治疗囊肿性痤疮方面的重要性,并表明挪威Roaccutan的处方常规是恰当的。